Free Trial
NASDAQ:CARM

Carisma Therapeutics (CARM) Stock Price, News & Analysis

Carisma Therapeutics logo
$0.40 +0.01 (+2.84%)
(As of 12/24/2024 04:10 PM ET)

About Carisma Therapeutics Stock (NASDAQ:CARM)

Key Stats

Today's Range
$0.38
$0.41
50-Day Range
$0.39
$1.11
52-Week Range
$0.38
$3.16
Volume
439,958 shs
Average Volume
339,554 shs
Market Capitalization
$16.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.94
Consensus Rating
Hold

Company Overview

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Carisma Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
68th Percentile Overall Score

CARM MarketRank™: 

Carisma Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 334th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Carisma Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Carisma Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Carisma Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Carisma Therapeutics are expected to grow in the coming year, from ($1.32) to ($1.26) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Carisma Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Carisma Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Carisma Therapeutics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.55% of the float of Carisma Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Carisma Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Carisma Therapeutics has recently decreased by 0.79%, indicating that investor sentiment is improving.
  • Dividend Yield

    Carisma Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Carisma Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.55% of the float of Carisma Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Carisma Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Carisma Therapeutics has recently decreased by 0.79%, indicating that investor sentiment is improving.
  • Search Interest

    Only 4 people have searched for CARM on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Carisma Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Carisma Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.57% of the stock of Carisma Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    44.27% of the stock of Carisma Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Carisma Therapeutics' insider trading history.
Receive CARM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARM Stock News Headlines

The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
See More Headlines

CARM Stock Analysis - Frequently Asked Questions

Carisma Therapeutics' stock was trading at $2.93 at the beginning of 2024. Since then, CARM stock has decreased by 86.4% and is now trading at $0.3990.
View the best growth stocks for 2024 here
.

Carisma Therapeutics, Inc. (NASDAQ:CARM) issued its earnings results on Thursday, November, 7th. The company reported ($0.31) earnings per share for the quarter, hitting the consensus estimate of ($0.31). The company earned $3.39 million during the quarter. Carisma Therapeutics had a negative trailing twelve-month return on equity of 957.20% and a negative net margin of 314.78%.

Top institutional investors of Carisma Therapeutics include Barclays PLC (1.32%), Barclays PLC (1.32%), Geode Capital Management LLC (0.62%) and Wexford Capital LP (0.08%).

Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Carisma Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
11/07/2024
Today
12/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CARM
Web
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.94
High Stock Price Target
$12.00
Low Stock Price Target
$0.70
Potential Upside/Downside
+1,138.1%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$-86,880,000.00
Net Margins
-314.78%
Pretax Margin
-315.75%

Debt

Sales & Book Value

Annual Sales
$20.27 million
Book Value
$0.66 per share

Miscellaneous

Free Float
36,502,000
Market Cap
$16.66 million
Optionable
No Data
Beta
1.44
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:CARM) was last updated on 12/25/2024 by MarketBeat.com Staff
From Our Partners